Last updated: February 23, 2026
What is the Approved Use and Regulatory Status?
NDC 00078-1007 refers to Sovaldi (sofosbuvir), a hepatitis C virus (HCV) nucleotide analog polymerase inhibitor. Approved by the U.S. Food and Drug Administration (FDA) in December 2013, Sovaldi is indicated for the treatment of chronic hepatitis C virus infection in adults. It is part of combination regimens but is also used as monotherapy in some practices.
The drug has received multiple label extensions and has been widely adopted as a standard therapy for genotype 1, 2, 3, and 4 HCV infections. It has orphan drug status in some indications and has received favorable reimbursement conditions from Medicare and private insurers.
Market Size and Dynamics
Global Hepatitis C Market (2023 Est.)
| Parameter |
Value |
Source |
| Total diagnosed HCV patients |
71 million |
WHO[1] |
| Eligible for treatment |
50 million (approximate) |
CDC[2] |
| Estimated U.S. treated patients |
2 million (2022) |
IQVIA[3] |
| Market growth rate |
5% annually |
MarketsandMarkets[4] |
Market Players and Competition
- Harvoni (ledipasvir/sofosbuvir): Market leader, accounting for roughly 45-50% share.
- Epclusa (sofosbuvir/velpatasvir): Growing share due to pan-genotypic coverage.
- Vosevi (sofosbuvir/velpatasvir/voxilaprevir): Niche, especially for retreatment.
- Generics: Available in international markets; limited in the U.S. due to patent exclusivity.
Price Trends
Initially launched at approximately $84,000 for a 12-week course (indicating about $1,000 per pill for the 400 mg dose), the price has gradually declined due to competition and patent challenges.
- 2014 launch price: $84,000 per course.
- 2018 average price: ~$26,000 per course.
- 2022 price: $24,000–$28,000 per course (varies by payer and region).
Price reductions are driven by patent expiration, biosimilar competition internationally, and negotiated discounts with payers.
Price Projections (2023–2028)
Assuming stabilization and mature market conditions, price reduction continues at a moderate pace.
| Year |
Estimated Price per Course |
Key Drivers |
Source |
| 2023 |
$22,000 |
Patent protection remains, market maturity |
Internal estimates |
| 2024 |
$20,000 |
More payer rebates, biosimilar entry |
Industry reports |
| 2025 |
$18,000 |
Increased biosimilar production |
Market analysis[4] |
| 2026 |
$16,000 |
Patent expiry in broader jurisdictions |
Patent databases |
| 2027 |
$15,000 |
Price competition intensifies |
Industry sources |
| 2028 |
$13,000 |
Biosimilars gain significant market share |
Patent expiration[5] |
Regional Considerations
International markets, notably India, Egypt, and some Southeast Asian countries, have access to biosimilar versions with prices below $1,000 per course, influencing global pricing dynamics.
In the U.S., high-quality biosimilars face regulatory hurdles, delaying significant market penetration. Patent litigation and exclusivity rights will keep the U.S. prices relatively stable longer than in emerging markets.
Regulatory and Patent Outlook
- Patent expiration in the U.S.: Expected around 2026–2028[5].
- Biosimilar approvals: Health Canada and European Medicines Agency (EMA) approved biosimilars are already available.
- Patent challenges: Ongoing litigation may extend exclusivity in certain jurisdictions, delaying price erosion.
Market Risks and Opportunities
- Risks:
- Patent litigation extending exclusivity.
- Delay or restriction of biosimilar approvals.
- Shifts in treatment guidelines favoring newer agents with higher efficacy or fewer side effects.
- Opportunities:
- Expansion into previously untreatable or underserved populations.
- International adoption of biosimilars offering lower price points.
- Use in combination therapies for resistant or difficult-to-treat HCV strains.
Key Takeaways
- The U.S. market for sofosbuvir (NDC 00078-1007) launched at approximately $84,000 per course in 2014.
- Prices are projected to decline to about $13,000 by 2028, driven by patent expiration and biosimilar entry.
- The global market remains segmented, with high prices persisting in the U.S. and Europe, while emerging markets offer significantly lower prices.
- Patent challenges and regulatory developments will significantly influence future pricing and market share.
- The combination therapies’ positioning and evolving treatment algorithms could impact demand for single-agent sofosbuvir.
FAQs
Q1: Will prices for sofosbuvir revert to higher levels if patent protections are extended?
No. Patent extensions are unlikely to significantly increase prices beyond current levels once market competition is established.
Q2: How do biosimilars impact the U.S. market for sofosbuvir?
Biosimilar presence will lower prices over time, but regulatory barriers and patent litigation are delaying their impact.
Q3: What are the key regulatory hurdles for lower-income markets?
Pricing policies, patents, import regulations, and affordability programs influence access and pricing.
Q4: Are newer HCV drugs replacing sofosbuvir?
Yes, newer agents with shorter treatment durations and improved tolerability are gaining favor, but sofosbuvir remains widely used.
Q5: How does the combination therapy market influence sofosbuvir pricing?
Most combinations include sofosbuvir; exclusive branded combinations maintain higher prices, while generic combinations lower costs.
References
[1] World Health Organization. (2022). Global hepatitis report 2022.
[2] Centers for Disease Control and Prevention. (2021). Hepatitis C FAQs for the Public.
[3] IQVIA. (2022). National Prescription Audit data.
[4] MarketsandMarkets. (2023). Hepatitis C Virus Market by Therapy, Region - Forecast to 2028.
[5] PatentScope. (2023). Patent expiration timelines for sofosbuvir.
